Keros Therapeutics (NASDAQ:KROS) VP Sells $12,594.96 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) VP Annita Tanini sold 1,224 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $12,594.96. Following the transaction, the vice president owned 45,144 shares of the company’s stock, valued at $464,531.76. The trade was a 2.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Trading Up 0.7%

Keros Therapeutics stock opened at $11.03 on Friday. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The company has a fifty day simple moving average of $10.71 and a 200 day simple moving average of $11.84. The company has a market cap of $218.72 million, a P/E ratio of -2.98 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -5.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on KROS shares. Leerink Partners reduced their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 16th. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.50.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Keros Therapeutics in the second quarter valued at approximately $29,898,000. Nantahala Capital Management LLC bought a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $15,091,483,000. Renaissance Technologies LLC boosted its stake in shares of Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after acquiring an additional 436,986 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $4,251,000. Finally, Caption Management LLC increased its holdings in shares of Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after acquiring an additional 291,997 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.